Protecting a long-overlooked immune organ during cancer treatment may meaningfully improve outcomes for lung cancer patients, according to new research from Mass General Brigham. The study, published in Annals of Oncology, found that unintended radiation exposure to the thymus during lung cancer treatment was linked to worse clinical results.
These findings suggest that doctors may eventually need to factor thymus protection into how radiation therapy is planned. This small gland, sitting just behind the breastbone, is where immune cells called T cells mature and learn to spot threats such as infections and cancer.
For years, doctors assumed the gland stopped mattering much once someone reached adulthood. Two earlier studies from the same research group upended that assumption, linking a well-functioning thymus to longevity and heart health.
That research also tied thymus health to cancer risk and to how well patients respond to modern immune-based cancer drugs. The gland does shrink over the decades, but the group’s prior work found it continues to perform meaningful functions in a large share of adults, with a stronger thymus linked to living longer and to facing less heart disease and cancer.
The gland sits near the chest, close enough to tumors there that it often catches stray radiation meant for the cancer itself, even though physicians never aim treatment at it directly. Whether that unintended exposure actually shapes patient outcomes had remained an open question.
To find out, the research team turned to artificial intelligence, combing through scans and treatment records for more than 1,000 patients being treated for an advanced, chest-confined form of lung cancer.
The researchers assessed how well each person’s thymus was functioning before treatment began, then tracked how much stray radiation it absorbed. Patients who entered treatment with healthy thymuses fared best overall.
But within that group, those whose thymus took on a heavier radiation load ended up living shorter lives on average and facing a greater chance their cancer would spread elsewhere in the body. Scans taken later showed the gland’s function had dropped in patients who absorbed the most radiation there.
The results also reinforced the team’s earlier work, which previously found that a stronger thymus translated into a much better response to a class of immune-boosting cancer drugs. Among patients in the new study who received one such drug, durvalumab, those whose thymus was still in good shape going into treatment seemed most vulnerable to the effects of radiation hitting that organ.
The team stressed that this was an observational study, meaning larger, forward-looking trials will need to confirm the pattern before doctors start routinely trying to shield the thymus during treatment planning.
Even so, it provides the strongest clinical evidence yet that keeping the thymus intact during treatment might genuinely help people with lung cancer live longer, underscoring the idea that beating cancer isn’t just about destroying the tumor, but also about keeping the body’s own defenses intact.
For companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) that are focused on developing immunotherapies indicated for several cancers, the health of the thymus offers a factor they could possibly evaluate while selecting patients to participate in clinical trials.
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com
TinyGems is powered by IBN
A financing gap is putting clean energy investment at risk, even as capital floods into the…
Krypton gas is emerging as an unlikely fix for one of quantum computing's manufacturing headaches. Cornell researchers…
The challenge for steel and other heavy industries is not finding carbon; it is finding…
Recurrent glioblastoma leaves patients with almost no effective treatments to fall back on. Standard therapies…
The United States sits on a significant coal resource base. FASForm produces six commercial outputs…
A mathematical study published in the journal Mathematical Business may have just offered a possible…